Tranzyme Pharma to Host Third Quarter 2012 Financial Results Conference Call on Friday, November 9, 2012

Tranzyme Pharma to Host Third Quarter 2012 Financial Results Conference Call
on Friday, November 9, 2012

RESEARCH TRIANGLE PARK, N.C., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM), today announced that it will host a conference call on
Friday, November 9, 2012 at 8:30 am ET to discuss third quarter 2012 financial
results. The Company will report third quarter 2012 financial results after
the close of the market on Thursday, November 8, 2012.

To participate in the live call, please dial (877) 670-9784 (U.S. and Canada)
or (970) 315-0430 (international), five to ten minutes prior to the start of
the call. A live audio webcast will also be available in the "Investors"
section of the Tranzyme Pharma website, www.tranzyme.com.

A replay of the conference call will be available from November 9, 2012 at
11:30 am ET through November 16, 2012. Investors may listen to the replay by
dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international),
with the passcode 39767587. The webcast will also be archived for on-demand
listening for 30 days at www.tranzyme.com.

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing novel, mechanism-based
therapeutics for the treatment of upper gastrointestinal (GI) motility
disorders. While approximately 40 percent of people in the U.S. are affected
by these persistent and recurring conditions which disrupt the normal movement
of food throughout the GI tract, there are a limited number of safe and
effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin
agonist for treating the symptoms associated with chronic upper GI motility
disorders. Enrollment is complete in a multinational Phase 2b trial evaluating
TZP-102 given once daily in diabetic patients with gastroparesis; top-line
data are expected by year-end 2012. Tranzyme has initiated a second Phase 2b
trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients
with gastroparesis; top-line data are expected in the first half of 2013. By
leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is
committed to pursuing first-in-class medicines to address areas of significant
unmet medical needs.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com
 
Press spacebar to pause and continue. Press esc to stop.